blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3463460

EP3463460 - AN ANTI-C5 ANTIBODY DOSING REGIMEN [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  30.04.2021
Database last updated on 02.11.2024
FormerExamination is in progress
Status updated on  31.07.2020
FormerRequest for examination was made
Status updated on  08.03.2019
FormerThe international publication has been made
Status updated on  16.12.2017
Formerunknown
Status updated on  11.07.2017
Most recent event   Tooltip30.04.2021Application deemed to be withdrawnpublished on 02.06.2021  [2021/22]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2019/15]
Inventor(s)01 / MEIER, Matthias
c/o Novartis Pharma AG
Postfach
4002 Basel / CH
02 / SLADE, Alan
c/o Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, New Jersey 07936 / US
03 / BALTCHEVA, Irina
c/o Novartis Pharma AG
Postfach
4002 Basel / CH
04 / MILTON, Mark
c/o Novartis Institutes for
BioMedical Research Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139 / US
05 / MUELLERSHAUSEN, Florian
c/o Novartis International AG
Lichtstrasse 35
4056 Basel / CH
 [2019/15]
Representative(s)Thompson, Sarah Louise
Novartis Pharma AG
Postfach
4002 Basel / CH
[2019/15]
Application number, filing date17734141.905.06.2017
[2019/15]
WO2017IB53303
Priority number, dateUS201662346687P07.06.2016         Original published format: US 201662346687 P
[2019/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017212391
Date:14.12.2017
Language:EN
[2017/50]
Type: A1 Application with search report 
No.:EP3463460
Date:10.04.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 14.12.2017 takes the place of the publication of the European patent application.
[2019/15]
Search report(s)International search report - published on:EP14.12.2017
ClassificationIPC:A61K39/395, C07K16/18, C07K16/40
[2019/15]
CPC:
C07K16/18 (EP,US); A61K39/395 (EP,US); A61K39/39541 (EP,US);
A61K39/3955 (EP,US); A61P37/06 (EP,US); C07K16/40 (EP,US);
A61K2039/505 (EP,US); A61K2039/54 (EP,US); A61K2039/545 (EP,US);
C07K2317/21 (US); C07K2317/76 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/15]
TitleGerman:ANTI-C5-ANTIKÖRPER-DOSIERSCHEMA[2019/15]
English:AN ANTI-C5 ANTIBODY DOSING REGIMEN[2019/15]
French:SCHÉMA POSOLOGIQUE D'UN ANTICORPS ANTI-C5[2019/15]
Entry into regional phase07.01.2019National basic fee paid 
07.01.2019Designation fee(s) paid 
07.01.2019Examination fee paid 
Examination procedure19.11.2018Amendment by applicant (claims and/or description)
07.01.2019Examination requested  [2019/15]
07.01.2019Date on which the examining division has become responsible
04.08.2020Despatch of a communication from the examining division (Time limit: M04)
15.12.2020Application deemed to be withdrawn, date of legal effect  [2021/22]
26.01.2021Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2021/22]
Fees paidRenewal fee
13.06.2019Renewal fee patent year 03
15.06.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO2007103134  (ALEXION PHARMA INC [US], et al) [X] 1,2,8,13,15-17,19,22,23 * page 5, line 5 - line 8 * * page 26, line 6 - page 27, line 7 *;
 [Y]WO2010015608  (NOVARTIS AG [CH], et al) [Y] 1-23 * table 1 * * sequences 1-10 * * example 7 * * table 7 *;
 [X]WO2010054403  (ALEXION PHARMA INC [US], et al) [X] 1,2,8,13,15-17,19,22,23 * page 16, line 5 * * page 17, line 5 - line 9 * * page 20, line 21 - line 27 * * page 92, line 28 - page 93, line 4 * * example 5 *;
 [X]WO2015023972  (ALEXION PHARMA INC [US]) [X] 1,2,8,13,15-17,19,22,23 * page 4, line 10 - line 19 * * page 8, line 23 - line 31 *;
 [YP]WO2016178980  (ALEXION PHARMA INC [US]) [YP] 1-23 * the whole document *;
 [YP]WO2017064615  (NOVARTIS AG [CH], et al) [YP] 1-23* the whole document *;
 [X]  - CHRISTOPHER K. JOHNSON ET AL, "Eculizumab use in kidney transplantation :", CURRENT OPINION IN ORGAN TRANSPLANTATION, US, (20151101), doi:10.1097/MOT.0000000000000249, ISSN 1087-2418, page 1, XP055398954 [X] 1,2,8,13,15-17,19,22,23 * page 648; table 2 * * page 647, paragraph 5 - page 649, paragraph 2 *

DOI:   http://dx.doi.org/10.1097/MOT.0000000000000249
 [X]  - BABAK J. ORANDI ET AL, "Eculizumab and Splenectomy as Salvage Therapy for Severe Antibody-Mediated Rejection After HLA-Incompatible Kidney Transplantation :", TRANSPLANTATION, GB, (20141001), vol. 98, no. 8, doi:10.1097/TP.0000000000000298, ISSN 0041-1337, pages 857 - 863, XP055399057 [X] 1,2,8,13,15-17,19,22,23 * abstract *

DOI:   http://dx.doi.org/10.1097/TP.0000000000000298
 [XI]  - M. D. STEGALL ET AL, "Terminal Complement Inhibition Decreases Antibody-Mediated Rejection in Sensitized Renal Transplant Recipients", AMERICAN JOURNAL OF TRANSPLANTATION, DK, (20111122), vol. 11, no. 11, doi:10.1111/j.1600-6143.2011.03757.x, ISSN 1600-6135, pages 2405 - 2413, XP055293016 [X] 1-3,8,13-17,19,22,23 * abstract * * page 2411, column l, paragraph 5 - page 2412, column l, paragraph 3 * * figure 1 * * page 2406, column r, paragraph 4 - page 2407, column l, paragraph 1 * [I] 4-7,9-12,18,20,21

DOI:   http://dx.doi.org/10.1111/j.1600-6143.2011.03757.x
 [X]  - MARK D. STEGALL ET AL, "The role of complement in antibody-mediated rejection in kidney transplantation", NATURE REVIEWS. NEPHROLOGY, (20121002), vol. 8, no. 11, doi:10.1038/nrneph.2012.212, ISSN 1759-5061, pages 670 - 678, XP055293015 [X] 1,2,8,13,15-17,19,22,23 * abstract * * page 672, column l, paragraph 2 - page 673, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.1038/nrneph.2012.212
 [XI]  - L. D. CORNELL ET AL, "Positive Crossmatch Kidney Transplant Recipients Treated With Eculizumab: Outcomes Beyond 1 Year : Late Outcomes After Eculizumab", AMERICAN JOURNAL OF TRANSPLANTATION, DK, (20150501), vol. 15, no. 5, doi:10.1111/ajt.13168, ISSN 1600-6135, pages 1293 - 1302, XP055399096 [X] 1,2,13,22,23 * page 1293, column r, paragraph 3 * * page 1294, column l, paragraph 4 * [I] 4-12,16-21

DOI:   http://dx.doi.org/10.1111/ajt.13168
 [X]  - JAMAL BAMOULID ET AL, "Advances in pharmacotherapy to treat kidney transplant rejection", EXPERT OPINION ON PHARMACOTHERAPY, LONDON, UK, (20150724), vol. 16, no. 11, doi:10.1517/14656566.2015.1056734, ISSN 1465-6566, pages 1627 - 1648, XP055399106 [X] 1,2,8,13,15-17,19,22,23 * table 2 * * page 1637, column r, paragraph 2 - paragraph 5 *

DOI:   http://dx.doi.org/10.1517/14656566.2015.1056734
 [Y]  - VOLZ CORNELIA ET AL, "Antibody therapies and their challenges in the treatment of age-related macular degeneration", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, (20150226), vol. 95, doi:10.1016/J.EJPB.2015.02.020, ISSN 0939-6411, pages 158 - 172, XP029296809 [Y] 1-23 * abstract * * page 164, column l, paragraph 2 - column r, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/j.ejpb.2015.02.020
by applicantWO9529697
 WO2007103549
 WO2010015608
 WO2011037362
 WO2011037395
 US8241628
 WO2014110438
 WO2015134894
 WO2015140304
    - ORANDI et al., American Journal of Transplantation, (20150000), vol. 15, pages 489 - 498
    - JOHNSON CK; LECA N., Curr Opin Organ Transplant, (20150000), vol. 20, no. 6, pages 643 - 51
    - STEGALL et al., American Journal of Transplantation, (20110000), vol. 11, pages 2405 - 2413
    - CORNELL, American Journal of Transplantation, (20150000), vol. 15, pages 1293 - 1302
    - JOHNSON et al., Curr Opin Organ Transplant, (20150000), vol. 20, no. 6, pages 643 - 51
    - FARKASH; COLVIN, Nat Rev Nephrol., (20120000), vol. 8, pages 255 - 7
    - SIS; HALLORAN, Curr Opin Organ Transplant., (20100000), vol. 15, pages 42 - 8
    - HIDALGO et al., Am J Transplant., (20100000), vol. 10, pages 1812 - 22
    - SOLEZ K et al., Kidney International, (19930000), vol. 44, pages 411 - 22
    - HAAS et al., Am J Transplant, (20140000), vol. 14, no. 2, pages 272 - 83
    - JOHN R et al., Transplantation, (20100000), vol. 90, pages 757 - 764
    - SHERNAN, SK et al., "Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass", Ann Thorac Surg., (20040300), vol. 77, no. 3, doi:doi:10.1016/j.athoracsur.2003.08.054, pages 942 - 9,949-50, XP002405124

DOI:   http://dx.doi.org/10.1016/j.athoracsur.2003.08.054
    - WIIRZNER R. et al., Complement Inflamm., (19910000), vol. 8, pages 328 - 40
    - NORIS M et al., Nature Revs Nephrology, (20120000), vol. 8, pages 622 - 33
    - RICKLIN; LAMBRIS, Nature Biotech., (20070000), vol. 25, pages 1365 - 75
    - STAHLI et al., Methods in Enzymology, (19830000), vol. 9, pages 242 - 253
    - KIRKLAND et al., J. Immunol., (19860000), vol. 137, pages 3614 - 3619
    - MOREL et al., Molec. Immunol., (19880000), vol. 25, pages 7 - 15
    - CHEUNG et al., Virology, (19900000), vol. 176, pages 546 - 552
    - MOLDENHAUER et al., Scand. J. Immunol., (19900000), vol. 32, pages 77 - 82
    - PARK WD et al., Am. J Transplant, (20030000), vol. 3, pages 952 - 960
    - GLOOR, Contrib. Nephrol., (20050000), vol. 146, pages 11 - 21
    - WARREN et al., Am. J Transplant., (20040000), vol. 4, pages 561 - 568
    - GLOTZ D et al., Am. J. Transplant., (20020000), vol. 2, pages 758 - 760
    - KUPIEC-WEGLINSKI, Ann. Transplant., (19960000), vol. 1, pages 34 - 40
    - MEHRA et al., Curr. Opin. Cardiol., (20030000), vol. 18, pages 153 - 158
    - KERMAN RH et al., Transplantation, (19960000), vol. 62, page 201
    - LEE PA et al., Clinical Transplants. Los Angeles: The Terasaki Foundation Laboratory, (20070000), page 219
    - COUZI et al., Transplantation, (20110000), vol. 91, page 527
    - LEGENDRE et al., Transplant Rev., (20130000), vol. 27, no. 3, pages 90 - 2
    - SCHWENGER; MORATH, Nephrol Dial Transplant., (20100000), vol. 25, no. 8, pages 2407 - 13
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.